Business Context and Reporting Period
This Form 8-K Current Report was filed by Black Diamond Therapeutics, Inc. on August 5, 2021, covering events occurring on August 3 and August 4, 2021. The filing details significant changes in the Company's executive leadership structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of Chief Medical Officer: Rachel Humphrey, M.D., terminated her employment effective August 4, 2021.
- Appointment of Interim Chief Medical Officer: Karsten Witt, M.D., Senior Vice President of Clinical Development, was appointed Interim Chief Medical Officer on August 3, 2021.
- Departure of Chief Scientific Officer: Christopher Roberts, Ph.D., resigned effective August 11, 2021, to become CEO at another company.
- Appointment of Chief Scientific Officer: Elizabeth Buck, Ph.D., Co-Founder and Executive Vice President, Discovery & Translational Sciences, was appointed Chief Scientific Officer on August 3, 2021.
Management Commentary, Risks, and Unusual Items
Separation Arrangements: Dr. Humphrey has been offered a separation agreement providing severance pay and benefits per her employment agreement. She will serve as an advisor until February 28, 2022. Her vested stock option exercise period is extended to the 12-month anniversary of the end of this advisory period.
Advisory Roles: Both departing executives, Dr. Humphrey and Dr. Roberts, will serve as advisors to the Company following their departures.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the operational impact of these leadership transitions.
Investor Verification Checklist
- Verify the specific terms of the separation agreement with Dr. Humphrey, including the total severance cost.
- Confirm the timeline for the permanent appointment of a Chief Medical Officer to replace the interim leader.
- Assess the impact of Dr. Roberts' departure on the Company's discovery and translational science pipeline.
- Review the Company's stock option plan to understand the implications of the extended exercise period for Dr. Humphrey.